ロード中...
Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology
Historically, patients with metastatic, persistent or recurrent cervical cancer had limited therapeutic options. Despite several Phase II/III clinical trials, the combination of cisplatin and paclitaxel remained the most effective chemotherapeutic regimen. In 2014, publication of Gynecologic Oncolog...
保存先:
| 出版年: | Future Oncol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5613942/ https://ncbi.nlm.nih.gov/pubmed/25760973 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.14.276 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|